Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 98 clinical trials
Nabilone for Non-motor Symptoms in Parkinson's Disease

This is an open-label extension study for participants of the randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal NMS-Nab Study, assessing the long-term safety and efficacy of nabilone for non-motor symptoms in patients with Parkinsons Disease.

parkinson's disease
motor symptoms
  • 150 views
  • 19 Feb, 2024
  • 1 location
The Effect of Intravenous Ketamine on Non Suicidal Self Injuries.

Participants will be recruited among hospitalized patients from the Tel-Aviv Medical Central psychiatric ward, who will present with either NSSI urges or behavior. The study design is a randomized control, double blind trial. Each patient will be assessed before, during, and after the trial by physical examination, blood tests and …

midazolam
hypertension
drug abuse
sedative
arrhythmia
  • 0 views
  • 19 Feb, 2024
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Immunotherapy may also contribute to the efficacy of systemic treatment by maintaining initial responses to chemotherapy. A double-blind, placebo-controlled phase 3 trial indicates that the addition of atezolizumab to standard chemotherapy significantly improves overall survival and progression-free survival compared with chemotherapy alone in treatment-nave patients with ED-SCLC who are in …

extensive stage sclc
non-small cell lung cancer
etoposide
immunodeficiency
congestive heart failure
  • 0 views
  • 19 Feb, 2024
To Evaluate the Safety Tolerability and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics profiles of TG-1000 in healthy volunteers, and to evaluate the food effect on pharmacokinetics of single oral dose of TG-1000 in healthy volunteers.

  • 0 views
  • 19 Feb, 2024
Efficacy and Safety of Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures on the Improvement of Blood Flow

This study was conducted to investigate the effects of daily supplementation of Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures on the Improvement of Blood Flow.

  • 0 views
  • 19 Feb, 2024
Safety and Immunogenicity Study of GX-19 a COVID-19 Preventive DNA Vaccine in Healthy Adults

The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.

dna vaccine
covid-19
body mass index
  • 0 views
  • 19 Feb, 2024
Combining Cereals With Pulses - Reduced Gastrointestinal Symptoms?

The aim of the study is to compare self-reported gastrointestinal symptoms and intestinal fermentation rates of the study products as measured by breath hydrogen and methane in adult population with self-reported mild abdominal sensitivity to pulses. The study products are a pulse products with two different cereals.

  • 0 views
  • 19 Feb, 2024
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations

lazertinib
adenocarcinoma
curative surgery
stage iv non-small cell lung cancer
lung adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Postprandial Effects of Functional Bread

This study investigates whether bread with added galactomannan, a soluble fiber, can reduce the postprandial glucose response in healthy overweight adults.

  • 0 views
  • 19 Feb, 2024
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

This trial will evaluate the safety, efficacy, pharmacokinetics, fecal concentrations, and fecal microbiome effects of ACX-362E [ibezapolstat] in patients with C. difficile infection (CDI). The current record applies only to Segment 2A, primary completion date August 2020.

white blood cell count
aspart
diarrhea
stool test
  • 0 views
  • 19 Feb, 2024